• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of Lanthanum Carbonate on Blood Pressure in CKD.

作者信息

Jamshidian Mitra S, Larive Brett, Gassman Jennifer, Raphael Kalani L, Chonchol Michel B, Ix Joachim H, Ginsberg Charles

机构信息

Department of Medicine, University of California San Diego, San Diego, CA.

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.

出版信息

Am J Kidney Dis. 2021 Aug;78(2):312-314. doi: 10.1053/j.ajkd.2020.12.012. Epub 2021 Jan 9.

DOI:10.1053/j.ajkd.2020.12.012
PMID:33428997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9012343/
Abstract
摘要

相似文献

1
Effect of Lanthanum Carbonate on Blood Pressure in CKD.碳酸镧对慢性肾脏病患者血压的影响
Am J Kidney Dis. 2021 Aug;78(2):312-314. doi: 10.1053/j.ajkd.2020.12.012. Epub 2021 Jan 9.
2
The Effects of Intensive Blood Pressure Lowering on Markers of Mineral Metabolism in Persons with CKD in SPRINT.强化降压对收缩压干预试验中慢性肾脏病患者矿物质代谢标志物的影响
Clin J Am Soc Nephrol. 2020 Jun 8;15(6):852-854. doi: 10.2215/CJN.01400220. Epub 2020 May 6.
3
Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD.2016年的高血压：慢性肾脏病中的血压目标、变异性及钠-葡萄糖协同转运蛋白2抑制剂治疗
Nat Rev Nephrol. 2017 Feb;13(2):75-76. doi: 10.1038/nrneph.2016.189. Epub 2016 Dec 28.
4
Resistant Hypertension in CKD.慢性肾脏病中的顽固性高血压
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):467-469. doi: 10.2215/CJN.14610920. Epub 2021 Feb 8.
5
In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?继收缩压干预试验之后：改善慢性肾脏病高血压管理的新目标？
Nephron. 2017;135(4):287-290. doi: 10.1159/000455130. Epub 2017 Feb 4.
6
Adherence to antihypertensive agents and blood pressure control in chronic kidney disease.抗高血压药物的依从性与慢性肾脏病的血压控制。
Am J Nephrol. 2010;32(6):541-8. doi: 10.1159/000321688. Epub 2010 Nov 2.
7
[New aspects of hypertension management in patients with chronic kidney disease].[慢性肾脏病患者高血压管理的新进展]
Rev Med Suisse. 2014 Sep 10;10(441):1668-72.
8
Mechanisms of Antihypertensive Effect of Chlorthalidone in Advanced Chronic Kidney Disease: A Causal Mediation Analysis.氯噻酮在晚期慢性肾脏病中降压作用的机制：因果中介分析。
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1025-1032. doi: 10.2215/CJN.0000000000000484. Epub 2024 Jun 12.
9
Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.慢性肾脏病矿物质和骨异常（CKD-MBD）从 3 期到透析阶段的磷处理和碳酸镧的三种强度。
Expert Opin Pharmacother. 2012 Nov;13(16):2337-53. doi: 10.1517/14656566.2012.730520. Epub 2012 Oct 4.
10
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.碳酸镧对慢性肾脏病IV期、V期及V-D期患者代谢性酸中毒的影响
Int Urol Nephrol. 2015 Jul;47(7):1165-71. doi: 10.1007/s11255-015-1003-3. Epub 2015 May 17.

引用本文的文献

1
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常（CKD-MBD）的磷结合剂。
Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.

本文引用的文献

1
Serum Phosphate and Microvascular Function in a Population-Based Cohort.基于人群的队列研究中血清磷酸盐与微血管功能。
Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1626-1633. doi: 10.2215/CJN.02610319. Epub 2019 Sep 20.
2
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.烟酰胺和碳酸镧对 CKD 患者血清磷酸盐和纤维母细胞生长因子 23 的影响：COMBINE 试验。
J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.
3
A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects.
饮食磷酸盐的控制增加可使健康人体的血压升高。
J Am Soc Nephrol. 2018 Aug;29(8):2089-2098. doi: 10.1681/ASN.2017121254. Epub 2018 Jul 18.
4
Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD: A Secondary Analysis from a Controlled Diet Balance Study.24 小时尿液磷作为 CKD 患者膳食磷摄入量和吸收的生物标志物：一项来自对照饮食平衡研究的二次分析。
Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1002-1012. doi: 10.2215/CJN.00390118. Epub 2018 Jun 19.
5
Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway.磷酸盐通过破坏一氧化氮途径对血管和内皮功能产生有害影响。
Nephrol Dial Transplant. 2017 Oct 1;32(10):1617-1627. doi: 10.1093/ndt/gfw252.
6
Lanthanum carbonate is not associated with QT interval modification in hemodialysis patients.碳酸镧与血液透析患者的QT间期改变无关。
Clin Pharmacol. 2010;2:89-93. doi: 10.2147/CPAA.S10218. Epub 2010 Jun 1.
7
Pharmacology of the phosphate binder, lanthanum carbonate.磷酸盐结合剂碳酸镧的药理学。
Ren Fail. 2011;33(2):217-24. doi: 10.3109/0886022X.2011.552821.
8
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.冠心病患者血清磷酸盐水平与心血管事件发生率之间的关系。
Circulation. 2005 Oct 25;112(17):2627-33. doi: 10.1161/CIRCULATIONAHA.105.553198.
9
Serum phosphate levels and mortality risk among people with chronic kidney disease.慢性肾病患者的血清磷酸盐水平与死亡风险
J Am Soc Nephrol. 2005 Feb;16(2):520-8. doi: 10.1681/ASN.2004070602. Epub 2004 Dec 22.